Cancer Treatment News and Research

RSS

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Northstar Healthcare acquires ownership interests in Texas based radiation therapy cancer treatment centers

Northstar Healthcare Inc. today announced that it entered into an agreement to acquire certain ownership interests in four physician owned radiation therapy cancer treatment centers from Dr. Chris Phan, a radiation oncologist. Dr. Phan is founder and Chief Executive Officer of Expert Oncology Network Solutions, LLC (EONS). EONS has been instrumental in developing and consulting with cancer centers across Texas.

28 Apr 2011

Scripps Research receives $1.9 million NIH grant for prostate cancer study

The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

In a new study published online in the journal Cancer, it was said that when faced with life-threatening cancer, minority patients like blacks may be more likely to drain their bank accounts to extend life than whites.

26 Apr 2011

Ohio State Roundtable to discuss about cancer drug development

The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Friends of Cancer Research are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

26 Apr 2011

Study: 80% of blacks more likely to spend all personal finances for cancer care

People in minority groups, especially black Americans, are more willing than their white counterparts to exhaust their personal financial resources to prolong life after being diagnosed with lung or colorectal cancer, according to a University of Alabama at Birmingham study published April 26, 2011, online in Cancer, the journal of the American Cancer Society.

26 Apr 2011

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Acupuncture provides long-lasting relief to hot flashes, heart palpitations and anxiety due to side effects of the hormone given to counteract testosterone, the hormone that induces prostate cancer, according to a study published in the April issue of the International Journal of Radiation Oncology-Biology-Physics, an official journal of the American Society for Radiation Oncology.

22 Apr 2011

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Ahead of World Malaria Day (25 April), EU-funded researchers have discovered that drugs originally designed to inhibit the growth of cancer cells can also kill the parasite that causes malaria. They believe this discovery could open up a new strategy for combating this deadly disease, which, according to World Health Organisation statistics, infected around 225 million and killed nearly 800 000 people worldwide in 2009.

21 Apr 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

Providing complete information about breast cancer treatment options often ends up overwhelming patients

Women who choose among different breast cancer treatment options make smarter choices when getting the information and making decisions in small doses rather than all at once, as is customary, a University of Michigan study found.

21 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

Sialix announces blood test results for early detection and treatment of breast cancer

Sialix, Inc. a pioneer in glycobiology, today announced the results of a study it participated in with researchers at the University of California, San Diego School of Medicine that could have significant impact in the prediction, early detection and treatment of cancer in humans.

20 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.

20 Apr 2011

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Researchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth.

20 Apr 2011

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

The new Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai opened today, bringing a range of multidisciplinary services under one roof and marking a great leap forward in care of breast cancer patients throughout the region.

19 Apr 2011

Bexion earns Biotech Innovation Award for new cancer treatment approach

Bexion Pharmaceuticals was named the Biotech Innovation Award winner at the Cincinnati USA Innovation Awards program sponsored by the Cincinnati Business Courier, the Cincinnati USA Regional Chamber and CincyTech.

19 Apr 2011

Radiologists to develop quantitative research tool that produces reliable numbers

The idea of probing the body's interior with radiation stretches back to experiments with X rays in the 1800s, but more than a century later, images taken with radiological scans still are not considered reliable enough to, for example, serve as the sole indicator of the efficacy of a cancer treatment.

16 Apr 2011

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme that recurs or progresses after receiving chemotherapy and radiation therapy.

15 Apr 2011

Cancer Treatment News and Research

Curis reports first quarter net loss of $6.8 million

Northstar Healthcare acquires ownership interests in Texas based radiation therapy cancer treatment centers

Scripps Research receives $1.9 million NIH grant for prostate cancer study

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

Ohio State Roundtable to discuss about cancer drug development

Study: 80% of blacks more likely to spend all personal finances for cancer care

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

Providing complete information about breast cancer treatment options often ends up overwhelming patients

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Sialix announces blood test results for early detection and treatment of breast cancer

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

Bexion earns Biotech Innovation Award for new cancer treatment approach

Radiologists to develop quantitative research tool that produces reliable numbers

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News